[go: up one dir, main page]

EA202092349A1 - LACTITOL AND ORAL DOSAGE FORM FOR NON-ALCOHOLIC FATTY LIVER DISEASE - Google Patents

LACTITOL AND ORAL DOSAGE FORM FOR NON-ALCOHOLIC FATTY LIVER DISEASE

Info

Publication number
EA202092349A1
EA202092349A1 EA202092349A EA202092349A EA202092349A1 EA 202092349 A1 EA202092349 A1 EA 202092349A1 EA 202092349 A EA202092349 A EA 202092349A EA 202092349 A EA202092349 A EA 202092349A EA 202092349 A1 EA202092349 A1 EA 202092349A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver disease
fatty liver
alcoholic fatty
lactitol
dosage form
Prior art date
Application number
EA202092349A
Other languages
Russian (ru)
Inventor
Владимир Викторович НЕСТЕРУК
Кирилл Константинович Сыров
Original Assignee
Общество С Ограниченной Ответственностью "Валента-Интеллект"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Валента-Интеллект" filed Critical Общество С Ограниченной Ответственностью "Валента-Интеллект"
Publication of EA202092349A1 publication Critical patent/EA202092349A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к области фармацевтической промышленности, а именно к применению лактитола в терапевтически эффективном количестве, предпочтительно в дозировке 1-20 г в сутки, для лечения и профилактики неалкогольной жировой болезни печени у млекопитающего, нуждающегося в этом. Изобретение обеспечивает расширение арсенала средств, эффективных в отношении терапии и профилактики неалкогольной жировой болезни печени.The invention relates to the pharmaceutical industry, namely to the use of lactitol in a therapeutically effective amount, preferably at a dosage of 1-20 g per day, for the treatment and prevention of non-alcoholic fatty liver disease in a mammal in need of it. EFFECT: invention provides an extension of the arsenal of agents effective for the treatment and prevention of non-alcoholic fatty liver disease.

EA202092349A 2018-04-03 2019-03-13 LACTITOL AND ORAL DOSAGE FORM FOR NON-ALCOHOLIC FATTY LIVER DISEASE EA202092349A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018111985A RU2692243C1 (en) 2018-04-03 2018-04-03 Using lactitol and an oral dosage form for treating and preventing non-alcoholic fatty liver disease
PCT/RU2019/000157 WO2019194703A1 (en) 2018-04-03 2019-03-13 Lactitol and an oral pharmaceutical form for non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
EA202092349A1 true EA202092349A1 (en) 2020-12-22

Family

ID=67038280

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092349A EA202092349A1 (en) 2018-04-03 2019-03-13 LACTITOL AND ORAL DOSAGE FORM FOR NON-ALCOHOLIC FATTY LIVER DISEASE

Country Status (5)

Country Link
KR (1) KR102569081B1 (en)
CN (1) CN111936148B (en)
EA (1) EA202092349A1 (en)
RU (1) RU2692243C1 (en)
WO (1) WO2019194703A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2113998B (en) * 1982-02-05 1985-08-29 Cv Chemie Combinatie Amsterdam Lactitol for the treatment of liver disease
WO2002039832A1 (en) * 2000-11-17 2002-05-23 Purac Biochem B.V. Use of lactitol for improving intestinal microflora

Also Published As

Publication number Publication date
CN111936148A (en) 2020-11-13
KR20200140326A (en) 2020-12-15
CN111936148B (en) 2023-07-14
RU2692243C1 (en) 2019-06-24
KR102569081B1 (en) 2023-08-23
WO2019194703A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
MX2021004431A (en) Novel processes.
EA202090871A1 (en) INHIBITION OF UBIKVITIN-SPECIFIC PEPTIDASE 30
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
MA34474B1 (en) AGONISTS OF GPR40
MX2017010982A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
PH12015500375A1 (en) Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling
EA201300471A1 (en) SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS
RU2014111069A (en) DOSAGE FORMS OF HISTONDIACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUTIN AND THEIR APPLICATION
MA40768A (en) MONO OR DI-SUBSTITUTE INDOLE DERIVATIVES AS DENGUE VIRUS REPLICATION INHIBITORS
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
EA202090276A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANEMIA
RU2018136872A (en) COMPOSITIONS CONTAINING 15-OH EPA AND WAYS OF THEIR APPLICATION
EA201691555A1 (en) METHODS OF TREATMENT AND PREVENTION OF KIDNEY DISEASES AND LIVER FATIAL DYSTROPHIES
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
MA53010B1 (en) FORMULATIONS OF AN AXL/MER INHIBITOR
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA202192199A1 (en) COMPOSITIONS CONTAINING CINNAMIC ACID AND METHODS OF THEIR APPLICATION
EA202190429A1 (en) Bioavailable oral dosage forms
MX395613B (en) ZINC-AND-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER.
MA41985B1 (en) Composition for cleansing the colon and treating gastrointestinal disorders
MA49839B1 (en) Bicyclic histone deacetylase inhibitors
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY
MA39448A1 (en) (R) -pirlindole and its pharmaceutically acceptable salts for medical use